Carfilzomib dose escalation study

Carfilzomib, pomalidomide, and dexamethasone for relapsed ...

★ ★ ★ ★ ☆

11/12/2015 · Treatment options for patients with heavily pretreated relapsed and/or refractory multiple myeloma remain limited. We evaluated a novel therapeutic regimen consisting of carfilzomib, pomalidomide, and dexamethasone (CPD) in an open-label, multicenter, phase 1, dose-escalation study.

Carfilzomib, pomalidomide, and dexamethasone for relapsed ...

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib ...

★ ★ ★ ★ ☆

4/15/2013 · Purpose: Carfilzomib, a selective proteasome inhibitor, has shown safety and efficacy in relapsed and/or refractory multiple myeloma. This phase I study in patients with relapsed or progressive multiple myeloma assessed the safety and tolerability of escalating doses of carfilzomib in combination with lenalidomide and low-dose dexamethasone (CRd) to identify the dose for a phase II expansion ...

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib ...

A Phase 1 Dose Escalation Study of the Safety and ...

★ ★ ★ ☆ ☆

11/15/2009 · Dose escalation. Carfilzomib doses administered ranged from 1.2 to 20 mg/m 2 (Table 2). Three patients were allowed intrasubject dose escalation by one or more dose levels but are reported in their starting dose level (one patient each in the 2.4, 6, and 11 mg/m 2 dose cohorts). The median number of 14-day cycles per patient was 4.8 (range, <1-16).

A Phase 1 Dose Escalation Study of the Safety and ...

Dose-Escalation Trial of Carfilzomib With and Without ...

★ ★ ★ ★ ★

11/30/2012 · OUTLINE: This is a dose-escalation study of carfilzomib. Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive carfilzomib intravenously (IV) over 30 minutes on days 1, 2, 8, 9, 15, and 16. ARM B: Patients receive carfilzomib as in Arm …

Dose-Escalation Trial of Carfilzomib With and Without ...

A Dose Escalation Study of Carfilzomib Taken With ...

★ ★ ☆ ☆ ☆

9/10/2015 · This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis. The trial begins with a dose escalation phase, in which the maximum tolerated and recommended dose will be …

A Dose Escalation Study of Carfilzomib Taken With ...

A Phase I Dose-Escalation Study of Carfilzomib in Patients ...

★ ★ ★ ★ ☆

12/6/2014 · Carfilzomib (CFZ) is a novel irreversible PI approved for relapsed/refractory multiple myeloma, with less neurologic toxicity than bortezomib, but its safety and efficacy in AL amyloidosis is not known. We report the first results of a multi-center, Phase I, dose-finding study of CFZ in AL ([NCT01789242][1]).

A Phase I Dose-Escalation Study of Carfilzomib in Patients ...

Once-weekly carfilzomib, pomalidomide, and low-dose ...

★ ★ ★ ★ ☆

1/30/2018 · Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study ... allowed an additional carfilzomib dose escalation to improve the efficacy ...

Once-weekly carfilzomib, pomalidomide, and low-dose ...

Evolution of carfilzomib dose and schedule in patients ...

★ ★ ★ ★ ★

The study enrolled patients in dose-escalation cohorts (carfilzomib dose range: 15–27 mg/m 2) and a dose-expansion cohort (20/27 mg/m 2). A total of 84 patients were enrolled, including those previously treated with bortezomib (77% of patients; 18% refractory) and/or lenalidomide (70% of …

Evolution of carfilzomib dose and schedule in patients ...

A Phase 1 Dose Escalation Study of the Safety and ...

★ ★ ☆ ☆ ☆

11/15/2009 · Dose escalation. Carfilzomib doses administered ranged from 1.2 to 20 mg/m 2 . Three patients were allowed intrasubject dose escalation by one or more dose levels but are reported in their starting dose level (one patient each in the 2.4, 6, and 11 mg/m 2 dose cohorts). The median number of 14-day cycles per patient was 4.8 (range, <1-16).

A Phase 1 Dose Escalation Study of the Safety and ...

Kyprolis (carfilzomib) dosing, indications, interactions ...

★ ★ ★ ☆ ☆

Medscape - Multiple myeloma dosing for Kyprolis (carfilzomib), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information

Kyprolis (carfilzomib) dosing, indications, interactions ...

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed ...

★ ★ ☆ ☆ ☆

Niesvizky R, Martin TG III, Bensinger WI, et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma ...

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed ...

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib ...

★ ★ ★ ☆ ☆

Request PDF on ResearchGate | Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma | Purpose ...

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib ...

Carfilzomib - News & Information - myelomabeacon.org

★ ★ ★ ★ ★

12/12/2018 · Carfilzomib (Kyprolis) news and resources for multiple myeloma patients, caregivers, and others interested in carfilzomib and multiple myeloma. Independent, up-to-date news and information for the multiple myeloma community. ... today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and car ...

Carfilzomib - News & Information - myelomabeacon.org

A Phase 1, Dose-Escalation Study (CHAMPION-1 ...

★ ★ ★ ★ ☆

12/7/2013 · Introduction: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US for the treatment of relapsed and refractory multiple myeloma (MM) (Kyprolis PI, 2012). The approved dose and schedule for single-agent CFZ is 20/27 mg/m 2 administered intravenously (IV) over 2–10 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle.

A Phase 1, Dose-Escalation Study (CHAMPION-1 ...

Phase 1/2 study of weekly carfilzomib, cyclophosphamide ...

★ ★ ★ ★ ★

11/16/2017 · The phase 1 portion used a 3+3 dose-escalation scheme to determine the maximum tolerated dose of weekly carfilzomib: 12 patients received …

Phase 1/2 study of weekly carfilzomib, cyclophosphamide ...

A study of carfilzomib with thalidomide and dexamethasone ...

★ ★ ★ ★ ★

This is a phase 1 study. The trial team need about 18 people to take part. There are 2 parts to this study. This summary is about the first part of the study. This is called the dose escalation part of the study. Part 1 The first few people to take part will have a low dose of carfilzomib and the standard treatment dose of thalidomide and ...

A study of carfilzomib with thalidomide and dexamethasone ...

Oncolytics Biotech® Announces First Patient Treated in ...

★ ★ ★ ☆ ☆

12/12/2018 · Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced …

Oncolytics Biotech® Announces First Patient Treated in ...

A Randomized Phase I Dose-Escalation Trial of Carfilzomib ...

★ ★ ★ ★ ★

OUTLINE: This is a dose-escalation study of carfilzomib. Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive carfilzomib intravenously (IV) over 30 minutes on days 1, 2, 8, 9, 15, and 16. ARM B: Patients receive carfilzomib as in Arm A and romidepsin IV over 4 hours on days 1, 8, and 15.

A Randomized Phase I Dose-Escalation Trial of Carfilzomib ...

Dose escalation | definition of dose escalation by Medical ...

★ ★ ★ ★ ☆

titled, "Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study," evaluates a study devised to test the safety of escalating the biologically-effective tumor dose via hypofractionated treatment regimens using 25 fractions over five weeks.

Dose escalation | definition of dose escalation by Medical ...

Carfilzomib Monograph for Professionals - Drugs.com

★ ★ ★ ☆ ☆

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. ... This phase Ib trial studies the side effects and best dose of carfilzomib when given together with ...

Carfilzomib Monograph for Professionals - Drugs.com

Clinical Trials Using Carfilzomib - National Cancer Institute

★ ★ ★ ★ ★

This was a dose-escalation study designed to determine the recommended dose for Japanese patients (phase I) and to investigate the antitumor activity and safety (phase II) of bortezomib ...

Clinical Trials Using Carfilzomib - National Cancer Institute
Study-bca-in-australia.html,Study-biochemistry-otago.html,Study-books-for-fe-exam.html,Study-by-janak-owner.html,Study-china-programme-qub.html